International Myotonic Dystrophy Consortium 2026 (IDMC-15)

Back

Zeleciment Basivarsen Targets the Underlying Cause of DM1 to Enable Functional Improvement in the Phase 1/2 ACHIEVE Trial

View

A Global Phase 3 Trial Assessing the Efficacy and Safety of Z-basivarsenin Myotonic Dystrophy Type 1

View

Health Insurance Profile and Health Insurance Literacy (HIL) in Myotonic Dystrophy Type 1 (DM1) (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.